Download presentation
Presentation is loading. Please wait.
1
Automated Output Example Slides
All these slides are produced automatically for you by the PromoPlanner4 with its in-build Share Insights Reporting Feature. Download Your Free Tool with Demo Data at
2
Input Data Summary The following slides summarise some of the key inputs to the model. They are an important anchor point and should be included in the output report.
3
Sales Forecast Actual Value GBP 2018 2019 2020 2021 2022 2023 2024 2025 Σ 186,805,152 193,728,388 +3.7% 209,010,755 +7.9% 237,688,974 +13.7% 260,735,192 +9.7% 284,438,859 +9.1% 283,460,842 -0.3% 288,703,688 +1.8% Painex 599,921 1,335,400 1,722,781 2,109,509 2,806,716 2,971,559 3,117,017 3,612,377 Antifectum 78,267 236,095 2,784,600 4,641,000 6,801,970 8,830,361 Boforce 3,746,761 5,415,371 5,805,084 5,973,927 5,892,465 5,677,041 5,450,492 5,211,524 Cardio Plus 54,395 132,877 262,598 1,128,908 2,213,546 2,379,246 2,527,237 Amelin 100,459 453,272 792,689 2,847,646 6,050,690 5,927,785 5,785,972 Luistene 792,082 809,884 849,370 862,965 874,162 865,592 854,265 840,019 Levigra 3,081,647 3,256,348 3,329,083 3,392,969 3,447,102 3,456,634 3,454,149 3,437,622 Motox 3,132,746 3,194,799 3,267,902 3,333,100 3,389,460 3,323,000 3,247,046 3,161,597 Urofax 10,184,174 11,506,631 13,121,299 14,656,943 16,031,314 17,319,133 18,494,398 19,542,476 Lempra 15,842,049 17,835,278 20,270,144 22,571,692 24,615,824 26,519,923 28,245,990 29,773,537 Sertrum 6,079,788 6,508,487 6,592,661 6,134,926 308,165 235,098 198,000 178,000 Etanos 19,045,118 14,412,043 14,969,928 15,357,194 15,556,457 15,473,336 15,106,052 14,695,275 Ingenuine 7,648,800 8,241,071 8,298,498 8,388,611 7,445,570 7,357,656 7,247,147 7,111,783 Quaxter 9,931,942 10,530,576 11,547,840 12,518,273 13,434,624 14,354,760 15,037,877 15,626,758 Kerzan 4,395,027 4,249,614 4,341,065 4,410,342 4,449,052 4,473,859 4,489,319 4,485,710 Taxis 3,076,062 2,388,966 2,004,138 812,698 200,187 180,621 151,872 132,100 Lysine 3,064,476 3,034,439 3,039,912 3,152,348 3,041,396 3,139,524 3,074,175 2,999,090 Cartox 37,604,491 35,648,686 35,852,907 35,516,601 35,135,006 34,303,211 33,444,825 32,492,342 Medecks 12,452,577 13,791,045 14,649,714 15,569,249 16,612,938 17,780,942 17,228,654 16,629,945 Profyle 5,298,672 5,457,992 7,975,915 10,090,957 11,518,323 12,422,929 12,909,360 13,319,751 Page 1/2 Short Description This is the Sales forecast as supplied by you for this exercise. It is important that this sales forecast is reviewed in combination with your submitted promotional investments as this forms the basis of the sales response analysis performed by the PromoPlanner. Comment 1 130
4
Sales Forecast 2018 2019 2020 2021 2022 2023 2024 2025 Tramalin
Actual Value GBP 2018 2019 2020 2021 2022 2023 2024 2025 Σ 186,805,152 193,728,388 +3.7% 209,010,755 +7.9% 237,688,974 +13.7% 260,735,192 +9.7% 284,438,859 +9.1% 283,460,842 -0.3% 288,703,688 +1.8% Tramalin 515,150 4,978,208 10,067,643 12,852,437 4,772,178 Bloodmine 7,821,968 14,185,158 13,777,213 19,026,935 18,900,096 18,714,382 18,286,551 17,805,254 Spinalin 914,709 1,679,806 2,330,562 4,583,405 6,317,770 7,731,433 9,223,106 10,611,733 Neckpain 8,788,185 7,146,107 8,660,476 10,060,694 11,193,711 12,039,000 12,608,275 13,100,990 Inflameless 427,500 888,021 1,153,155 1,364,985 1,613,294 1,882,177 1,986,288 2,077,278 Fungalin 5,860,036 6,693,047 7,440,438 7,951,340 8,156,630 8,018,806 7,855,924 7,667,984 Stomax 6,725,664 15,465,240 22,423,800 23,555,000 23,752,178 Bloodpump 3,296,270 3,407,723 3,704,538 3,848,943 3,986,280 4,114,870 4,232,851 4,328,329 Ferexis 13,720,151 11,957,042 13,126,566 13,005,114 13,514,613 13,901,900 14,081,030 14,194,288 Page 2/2 Short Description This is the Sales forecast as supplied by you for this exercise. It is important that this sales forecast is reviewed in combination with your submitted promotional investments as this forms the basis of the sales response analysis performed by the PromoPlanner. Comment 2 130
5
Cost Of Goods 2018 2019 2020 2021 2022 2023 2024 2025 Painex 13% Antifectum 19% Boforce 4% Cardio Plus Amelin Luistene 6% Levigra 8% Motox 11% Urofax 17% Lempra 50% 55% Sertrum 35% 52% 66% Etanos 12% 20% 27% Ingenuine Quaxter 10% Kerzan Taxis 5% 34% Lysine Cartox 7% 32% Medecks 15% Profyle 21% Page 1/2 Short Description As the PromoPlanner optimizes your long term profitability, it is important that the Cost of Goods of your brands is taken into consideration. COGs can vary significantly between different products particularly between those that have patent protection and those that do not. Please ensure that any future expected price changes are taken into consideration in your calculations. Comment 3 130
6
Cost Of Goods 2018 2019 2020 2021 2022 2023 2024 2025 Tramalin 19% 42% Bloodmine 26% Spinalin 14% Neckpain 18% 24% 28% Inflameless 22% Fungalin 5% Stomax 56% Bloodpump Ferexis Page 2/2 Short Description As the PromoPlanner optimizes your long term profitability, it is important that the Cost of Goods of your brands is taken into consideration. COGs can vary significantly between different products particularly between those that have patent protection and those that do not. Please ensure that any future expected price changes are taken into consideration in your calculations. Comment 4 130
7
Initial FTEs Actual Value GBP 2018 2019 2020 2021 2022 2023 2024 2025 Σ 235 234 -0.5% 236 +0.6% 241 +2.4% 243 +0.8% 246 +1.3% 247 +0.0% Painex 1.3 2.2 4.3 Antifectum 0.7 2.4 2.6 Boforce 1.7 1.6 2.1 2.3 Cardio Plus 0.3 0.4 Amelin 0.1 Luistene 1.9 Levigra Motox 4.4 4.6 4.0 Urofax 3.9 Lempra 9.4 9.3 10.8 Sertrum 11.3 12.1 12.0 10.0 Etanos 6.7 Ingenuine 13.5 12.3 12.8 Quaxter 32.4 32.3 31.9 30.5 31.0 33.7 Kerzan 13.9 11.4 Taxis 9.2 7.1 6.3 2.7 Lysine 6.5 10.1 7.9 6.4 Cartox 33.5 28.4 28.6 26.4 28.9 Medecks 7.7 11.5 13.3 Profyle 3.7 4.8 5.1 5.0 Page 1/2 Short Description These are the FTEs you have submitted that are expected to drive the Sales Forecast. Do make sure that these are annualized FTE numbers. As an example if you have 10 FTEs promoting a brand for half the year, you need to enter 5 FTEs in this table. Please also ensure that all third party or contract sales force personnel are included in this table. Comment 5 130
8
Initial FTEs Actual Value GBP 2018 2019 2020 2021 2022 2023 2024 2025 Σ 235 234 -0.5% 236 +0.6% 241 +2.4% 243 +0.8% 246 +1.3% 247 +0.0% Tramalin 0.9 3.0 3.7 Bloodmine 17.4 16.5 15.9 14.4 13.8 Spinalin 5.6 7.5 7.7 8.4 8.3 7.2 Neckpain 1.3 2.7 3.8 3.9 Inflameless 2.8 3.1 3.4 3.3 Fungalin 2.6 4.1 5.2 6.7 Stomax 0.2 0.8 Bloodpump 9.0 9.5 9.3 13.3 Ferexis 33.2 28.6 28.4 37.1 34.7 31.0 Page 2/2 Short Description These are the FTEs you have submitted that are expected to drive the Sales Forecast. Do make sure that these are annualized FTE numbers. As an example if you have 10 FTEs promoting a brand for half the year, you need to enter 5 FTEs in this table. Please also ensure that all third party or contract sales force personnel are included in this table. Comment 6 130
9
Rep Costs 2018 2019 2020 2021 2022 2023 2024 2025 Painex Antifectum
Actual Value GBP 2018 2019 2020 2021 2022 2023 2024 2025 Change +2.6% +3.6% +5.5% +3.8% +4.4% +3.0% Painex 115,252 118,816 122,380 126,052 129,833 133,728 137,740 141,873 Antifectum Boforce Cardio Plus Amelin Luistene Levigra Motox Urofax Lempra Sertrum Etanos Ingenuine Quaxter Kerzan Taxis Lysine Cartox Medecks Profyle Page 1/2 Short Description These Fully Loaded costs will be multiplied by the FTEs you have supplied to determine your sales force investment. They typically increase over time due to inflation. There may be different costs for some brands for example if promoted by highly specialized hospital reps compared to less specialized primary care or contract reps. Comment 7 130
10
Rep Costs 2018 2019 2020 2021 2022 2023 2024 2025 Tramalin Bloodmine
Actual Value GBP 2018 2019 2020 2021 2022 2023 2024 2025 Change +2.6% +3.6% +5.5% +3.8% +4.4% +3.0% Tramalin 115,252 118,816 122,380 126,052 129,833 133,728 137,740 141,873 Bloodmine Spinalin Neckpain Inflameless Fungalin Stomax Bloodpump Ferexis Page 2/2 Short Description These Fully Loaded costs will be multiplied by the FTEs you have supplied to determine your sales force investment. They typically increase over time due to inflation. There may be different costs for some brands for example if promoted by highly specialized hospital reps compared to less specialized primary care or contract reps. Comment 8 130
11
Other Promo Expenditures
Actual Value GBP 2018 2019 2020 2021 2022 2023 2024 2025 Σ 13,445,896 14,225,587 +5.8% 16,159,238 +13.6% 22,510,921 +39.3% 22,004,604 -2.2% 21,598,673 -1.8% 20,388,621 -5.6% 19,208,167 -5.8% Painex 59,640 89,460 119,280 149,100 178,920 208,740 238,560 Antifectum 752,400 2,143,200 1,748,400 1,470,000 1,375,200 Boforce 166,992 137,172 Cardio Plus 39,459 46,238 49,383 52,527 Amelin 9,689 11,353 12,125 12,897 Luistene 80,514 83,496 92,442 Levigra 172,956 190,848 Motox 279,984 294,624 292,236 Urofax 546,919 547,675 527,814 518,868 575,368 632,271 689,176 Lempra 1,276,145 1,277,909 1,231,566 1,210,692 1,342,525 1,475,300 1,608,077 Sertrum 268,380 200,000 Etanos 559,006 424,845 446,087 459,470 Ingenuine 724,030 730,533 756,102 782,565 Quaxter 913,680 1,013,880 1,073,520 Kerzan 360,104 381,100 408,534 418,673 Taxis 315,192 284,004 293,952 304,236 260,000 220,000 Lysine 425,532 394,197 365,200 336,228 Cartox 1,234,549 1,192,801 1,180,561 1,157,017 Medecks 524,833 506,941 620,257 578,509 584,473 596,401 Profyle 289,851 715,681 Page 1/2 Short Description This table shoes the non sales-force driven promotional investments you are planning currently. It may include print advertising, e-detailing, web content production, tele-marketing, other digital media and non digital promotional channels. If samples have not been considered as part of your fully loaded rep costs, please ensure the cost of samples is included here if relevant. Comment 9 130
12
Other Promo Expenditures
Actual Value GBP 2018 2019 2020 2021 2022 2023 2024 2025 Σ 13,445,896 14,225,587 +5.8% 16,159,238 +13.6% 22,510,921 +39.3% 22,004,604 -2.2% 21,598,673 -1.8% 20,388,621 -5.6% 19,208,167 -5.8% Tramalin 298,200 656,041 834,961 1,073,521 1,431,362 1,100,000 1,000,000 Bloodmine 1,088,799 758,975 736,555 876,500 954,032 1,031,564 1,109,096 Spinalin 544,484 477,121 518,869 Neckpain 506,941 536,761 Inflameless 333,984 241,542 Fungalin 250,489 271,601 282,336 Stomax 600,000 1,200,000 4,800,000 4,200,000 3,600,000 Bloodpump 238,560 256,452 268,679 278,221 Ferexis 2,141,195 1,985,990 2,165,909 3,011,712 3,023,454 2,878,573 1,795,840 711,470 Page 2/2 Short Description This table shoes the non sales-force driven promotional investments you are planning currently. It may include print advertising, e-detailing, web content production, tele-marketing, other digital media and non digital promotional channels. If samples have not been considered as part of your fully loaded rep costs, please ensure the cost of samples is included here if relevant. Comment 10 130
13
Strategic Output These are the product-level insights resulting from the Strategic Analysis section of the PromoPlanner. This step is automatic and fast.
14
Percentages relate to proportion of top 10 brand sales
Base Case Summary I – Sales Forecast Input Data Visualisation This slide shows your input data in a graphical form for easy review. Rank Brand 5 Years Sales Forecast 1 Cartox 176,456,411 2 Lempra 111,812,861 3 Bloodmine 84,603,784 4 Medecks 78,403,888 5 Etanos 75,768,958 6 Urofax 72,635,320 7 Ferexis 65,505,235 8 Quaxter 62,386,073 9 Neckpain 49,099,988 10 Profyle 47,466,116 Percentages relate to proportion of top 10 brand sales 11 130
15
Base Case Summary II Input Data Visualization
This slide shows your input data in a graphical form for easy review.
16
Total Sales One Year (Butterfly)
Promotional Budget 2019 Sales 2019 5,384,128 Ferexis 11,957,042 4,851,637 Quaxter 10,530,576 4,567,175 Cartox 35,648,686 2,826,373 Bloodmin… 14,185,158 2,394,779 Lempra 17,835,278 2,191,970 Ingenuin… 8,241,071 1,873,325 Medecks 13,791,045 1,723,721 Kerzan 4,249,614 1,706,054 Sertrum 6,508,487 1,594,239 Lysine 3,034,439 1,385,204 Bloodpum… 3,407,723 1,368,241 Spinalin 1,679,806 1,285,998 Profyle 5,457,992 1,220,912 Etanos 14,412,043 1,127,598 Taxis 2,388,966 1,022,939 Urofax 11,506,631 857,564 Neckpain 7,146,107 845,451 Inflamel… 888,021 817,414 Motox 3,194,799 758,747 Fungalin 6,693,047 1-20
17
Total Sales One Year (Butterfly)
Promotional Budget 2019 Sales 2019 600,000 Stomax 440,362 Levigra 3,256,348 357,098 Boforce 5,415,371 309,246 Luistene 809,884 298,200 Tramalin 243,921 Painex 1,335,400 Antifect… Cardio P… 54,395 Amelin 100,459 21-29
18
Total Sales Five Years (Butterfly)
Promotional Budget Sales 33,266,670 Ferexis 65,505,235 25,425,681 Quaxter 62,386,073 23,663,541 Cartox 176,456,411 14,636,059 Stomax 44,614,704 14,163,563 Bloodmin… 84,603,784 12,823,977 Lempra 111,812,861 11,599,009 Ingenuin… 39,731,406 10,272,698 Medecks 78,403,888 9,212,389 Kerzan 21,923,932 8,433,611 Spinalin 22,642,976 8,259,608 Sertrum 19,779,337 7,834,679 Bloodpum… 19,062,354 6,886,762 Lysine 15,407,619 6,861,528 Antifect… 7,739,962 6,746,513 Profyle 47,466,116 6,475,762 Etanos 75,768,958 5,470,763 Urofax 72,635,320 5,401,966 Tramalin 28,413,438 4,989,143 Neckpain 49,099,988 4,580,426 Taxis 5,586,610 1-20
19
Total Sales Five Years (Butterfly)
Promotional Budget Sales 4,477,771 Fungalin 38,260,261 4,186,760 Motox 16,508,261 3,705,994 Inflamel… 6,901,632 2,469,682 Painex 10,945,965 2,438,271 Levigra 16,882,136 1,883,501 Boforce 28,763,888 1,696,302 Luistene 4,261,973 178,138 Cardio P… 3,792,324 60,003 Amelin 10,244,756 21-29
20
Carryover Assessment 2019 2020 2021 2022 2023 2024 2025 Painex
167% 103% 96% 100% 82% 81% 90% Antifectum 116% 858% 120% 113% 105% Boforce 128% 97% 93% 88% 86% 85% 84% Cardio Plus 244% 198% 371% 179% 99% 98% Amelin 451% 169% 352% 210% Luistene 77% 79% 76% 74% 73% Levigra 89% 87% Motox 83% 80% Urofax 95% 94% Lempra 92% 91% Sertrum 3% 43% 47% 50% Etanos 66% Ingenuine 72% Quaxter Kerzan 78% Taxis 61% 64% 27% 16% 53% 51% Lysine Cartox Medecks Profyle 118% 106% Page 1/2 Short Description Carryover is a measure of each products sales momentum. The percentage relates to the amount of sales of the previous years forecast that is expected to CARRYOVER into this year if we assume there to be no promotional investment in the current year. Comment 17 130
21
Carryover Assessment 2019 2020 2021 2022 2023 2024 2025 Tramalin
678% 161% 106% 28% 81% Bloodmine 137% 79% 112% 83% 82% 80% Spinalin 119% 100% 136% 98% 95% Neckpain 70% 102% 99% 96% 94% 92% 91% Inflameless 127% 93% 89% 84% Fungalin Stomax 162% 117% 88% 85% Bloodpump 76% 74% 73% Ferexis 68% 75% 78% Page 2/2 Short Description Carryover is a measure of each products sales momentum. The percentage relates to the amount of sales of the previous years forecast that is expected to CARRYOVER into this year if we assume there to be no promotional investment in the current year. Comment 18 130
22
Promotional Impact Segments
All Products Future Promotion Past Promotion 34,012,609 64,462,465 92,431,541 118,888,913 146,018,791 170,054,722 191,374,334 100,423,498 209,819,104 360,752,848 549,704,416 751,437,581 970,324,432 Cumulated Impact of 2019 Promotional Effort (Payback) Cumulated Impact of Continuous promotion 85% 89% 92% 91% 84% 86% Carryover 19 130
23
Promotional Impact Segments
Painex Future Promotion Past Promotion 334,475 679,895 1,011,282 1,342,441 1,614,466 1,835,892 2,034,951 1,023,578 2,141,405 3,957,118 6,114,635 8,569,032 11,585,718 Cumulated Impact of 2019 Promotional Effort (Payback) Cumulated Impact of Continuous promotion 167% 103% 96% 100% 82% 81% 90% Carryover 20 130
24
Promotional Impact Segments
Antifectum Future Promotion Past Promotion 78,267 314,362 3,098,962 7,739,962 14,541,932 23,372,293 Cumulated Impact of 2019 Promotional Effort (Payback) Cumulated Impact of Continuous promotion 0% 116% 858% 120% 113% 105% Carryover 21 130
25
Promotional Impact Segments
Boforce Future Promotion Past Promotion 610,081 1,202,620 1,756,207 2,245,618 2,664,977 3,021,543 3,322,101 1,748,039 3,361,647 5,399,266 7,773,232 10,415,238 13,259,425 Cumulated Impact of 2019 Promotional Effort (Payback) Cumulated Impact of Continuous promotion 128% 97% 93% 88% 86% 85% 84% Carryover 22 130
26
Incremental Sales Long Term (Butterfly)
Promotional Budget 2019 Incremental Sales Long-Term 2019 5,384,128 Ferexis 8,164,602 4,851,637 Quaxter 8,626,489 4,567,175 Cartox 18,357,937 2,826,373 Bloodmin… 15,166,848 2,394,779 Lempra 13,091,512 2,191,970 Ingenuin… 5,085,235 1,873,325 Medecks 8,538,505 1,723,721 Kerzan 2,908,609 1,706,054 Sertrum 2,414,750 1,594,239 Lysine 2,350,786 1,385,204 Bloodpum… 2,836,293 1,368,241 Spinalin 3,893,619 1,285,998 Profyle 4,741,499 1,220,912 Etanos 7,189,207 1,127,598 Taxis 668,053 1,022,939 Urofax 7,446,086 857,564 Neckpain 4,697,973 845,451 Inflamel… 1,401,745 817,414 Motox 2,092,725 758,747 Fungalin 3,780,966 1-20
27
Incremental Sales Long Term (Butterfly)
Promotional Budget 2019 Incremental Sales Long-Term 2019 600,000 Stomax 440,362 Levigra 1,865,998 357,098 Boforce 2,482,852 309,246 Luistene 615,311 298,200 Tramalin 243,921 Painex 1,453,842 Antifect… Cardio P… 1,981,482 Amelin 3,334,291 21-29
28
ROI Long Term 2019 (Butterfly)
Promotional Budget 2019 ROI 2019 5,384,128 Ferexis 71% 4,851,637 Quaxter 161% 4,567,175 Cartox 350% 2,826,373 Bloodmin… 360% 2,394,779 Lempra 539% 2,191,970 Ingenuin… 225% 1,873,325 Medecks 390% 1,723,721 Kerzan 160% 1,706,054 Sertrum 126% 1,594,239 Lysine 126% 1,385,204 Bloodpum… 152% 1,368,241 Spinalin 230% 1,285,998 Profyle 342% 1,220,912 Etanos 493% 1,127,598 Taxis 77% 1,022,939 Urofax 621% 857,564 Neckpain 435% 845,451 Inflamel… 134% 817,414 Motox 231% 758,747 Fungalin 508% 1-20
29
ROI Long Term 2019 (Butterfly)
Promotional Budget 2019 ROI 2019 600,000 Stomax 0% 440,362 Levigra 396% 357,098 Boforce 716% 309,246 Luistene 194% 298,200 Tramalin 0% 243,921 Painex 576% Antifect… 0% Cardio P… 0% Amelin 0% 21-29
30
Promotional ROI 2019 2020 2021 Painex Antifectum Boforce Cardio Plus
Portfolio Average: 285% 279% 272% Painex 576% 467% 381% Antifectum 316% 232% Boforce 716% 640% 597% Cardio Plus Amelin 4,775% Luistene 194% 200% 174% Levigra 396% 385% 358% Motox 231% 227% Urofax 621% 635% 636% Lempra 539% 516% 469% Sertrum 126% 89% 47% Etanos 493% 485% 448% Ingenuine 225% 206% 201% Quaxter 161% 170% 178% Kerzan 160% 159% 156% Taxis 77% 51% 30% Lysine 128% 146% Cartox 350% 327% 303% Medecks 390% 377% Profyle 342% 446% 420% Page 1/2 Short Description The ROI Assessment is shown for the entire Portfolio and for each product. Comment 53 130
31
Promotional ROI 2019 2020 2021 Tramalin Bloodmine Spinalin Neckpain
Portfolio Average: 285% 279% 272% Tramalin 1,778% 626% Bloodmine 360% 304% 328% Spinalin 230% 256% 329% Neckpain 435% 472% 462% Inflameless 134% 131% 148% Fungalin 508% 484% 454% Stomax 467% Bloodpump 152% 156% Ferexis 71% 75% 60% Page 2/2 Short Description The ROI Assessment is shown for the entire Portfolio and for each product. Comment 54 130
32
FTE Base Plan Optimized Alert Level 2018 2019 2020 2021 2022 2023 2019
Σ 235 234 236 241 243 246 218 215 Painex 1.30 2.2 4.3 3.8 3.5 4.0 Antifectum 0.70 2.4 2.6 0.59 3.6 Boforce 1.70 1.60 2.1 2.3 4.7 4.2 4.4 Cardio Plus 0.30 0.40 1.79 Amelin 0.10 2.8 1.90 Luistene 1.25 1.19 1.31 Levigra Motox 4.6 3.4 3.3 3.2 Urofax 3.9 12.0 Lempra 9.4 9.3 10.8 16.0 15.3 Sertrum 11.3 12.1 10.0 2.0 1.07 0.26 0.22 Etanos 6.7 11.9 11.0 11.1 Ingenuine 13.5 12.3 12.8 9.0 8.0 7.7 8.2 Quaxter 32 31 34 19.1 20 21 22 Kerzan 13.9 11.4 5.9 5.8 6.0 6.1 Taxis 9.2 7.1 6.3 2.7 0.98 0.67 0.36 0.17 0.20 Lysine 6.5 10.1 7.9 6.4 Cartox 28 29 26 30 27 Medecks 11.5 13.3 17.6 16.4 17.2 16.1 Profyle 3.7 4.8 5.1 5.0 7.6 10.4 8.6 7.8 Page 1/2 2019 Under Over Description This table compares the Base Case FTE plan you have submitted with the PromoPlanner recommendation. The coloured bars are a representation of the extent to which your current plan is over or under invested. Bars pointing to the left indicate your current plan is under-resourcing the brand. Bars pointing to the right are over resourcing your brand. The colours and length represent the severity of the situation. Red bars suggest action needs to be taken now, yellow bars suggest the situation needs to be watched closely, green bars suggest the plan is fine. The bars only comment on the first year of optimisation. 55 130
33
FTE Base Plan Optimized Alert Level 2018 2019 2020 2021 2022 2023 2019
Σ 235 234 236 241 243 246 218 215 Tramalin 0.90 3.0 3.7 3.9 2.2 4.1 2.9 Bloodmine 17.4 16.5 15.9 14.4 13.8 24 18.1 21 15.6 14.8 Spinalin 5.6 7.5 7.7 8.4 8.3 7.2 9.3 10.5 11.2 10.1 Neckpain 1.30 2.7 3.8 5.3 8.1 7.4 7.0 Inflameless 2.8 3.1 3.4 3.3 1.48 1.91 2.1 Fungalin 2.6 5.2 6.7 8.2 8.0 8.5 Stomax 0.20 0.80 0.24 0.74 0.76 Bloodpump 9.0 9.5 13.3 5.4 6.4 Ferexis 33 29 28 37 35 31 7.3 7.8 Page 2/2 2019 Under Over Description This table compares the Base Case FTE plan you have submitted with the PromoPlanner recommendation. The coloured bars are a representation of the extent to which your current plan is over or under invested. Bars pointing to the left indicate your current plan is under-resourcing the brand. Bars pointing to the right are over resourcing your brand. The colours and length represent the severity of the situation. Red bars suggest action needs to be taken now, yellow bars suggest the situation needs to be watched closely, green bars suggest the plan is fine. The bars only comment on the first year of optimisation. 56 130
34
Operational Output These are the customer/product/team/marketing channel insights resulting from the Operational & Tactical Analysis section of the PromoPlanner. It will require additional input on your customers and your market landscape, so the process takes a little longer. But what you get is really worth it.
35
Value Split This is line 2 This is line 3 This is line 4 Description
Comment 57 130
36
Value Split Painex Antifectum Boforce Cardio Plus Amelin Luistene
GPs Retail Pharmacies Pediatrician Gynecologist - Obstetri.. Internal Medicine Surgery Orthopedics Psychiatry Otolaryngology Cardiologists Dermatology Urology Neurologists Pulmonologist Oncology Nurse Oncologist Endocrinologist Nefrologist Rheumatologist Mastologists Painex 21% 9% 4% Antifectum 30% 1% 5% 10% Boforce 8% 49% 19% Cardio Plus 24% 57% Amelin 25% 51% Luistene 12% Levigra 23% 20% Motox Urofax 29% 38% Lempra 48% Sertrum Etanos 40% Ingenuine Value Split Products 1 to 13 58 130
37
Value Split Painex Antifectum Boforce Cardio Plus Amelin Luistene
Neurosurgery Trauma Specialist Hematologist Anesthesiologists Infect. Spec. Allergist Emergency Spec. Geriatrician Patients Institutions (Promotion.. Patient Advocacy Groups Nurses Painex 26% 4% 8% Antifectum 10% 5% Boforce Cardio Plus Amelin Luistene 19% Levigra Motox Urofax Lempra Sertrum 48% Etanos 25% Ingenuine 80% Value Split Products 1 to 13 59 130
38
Value Split Quaxter Kerzan Taxis Lysine Cartox Medecks Profyle
GPs Retail Pharmacies Pediatrician Gynecologist - Obstetri.. Internal Medicine Surgery Orthopedics Psychiatry Otolaryngology Cardiologists Dermatology Urology Neurologists Pulmonologist Oncology Nurse Oncologist Endocrinologist Nefrologist Rheumatologist Mastologists Quaxter 49% 4% 34% Kerzan 10% 1% 78% Taxis 15% 73% Lysine 29% 68% Cartox 5% Medecks 21% Profyle Tramalin 76% Bloodmine 2% 19% Spinalin 95% Neckpain 38% Inflameless 67% Fungalin Value Split Products 14 to 26 60 130
39
Value Split Quaxter Kerzan Taxis Lysine Cartox Medecks Profyle
Neurosurgery Trauma Specialist Hematologist Anesthesiologists Infect. Spec. Allergist Emergency Spec. Geriatrician Patients Institutions (Promotion.. Patient Advocacy Groups Nurses Quaxter 5% Kerzan 10% Taxis Lysine Cartox Medecks 45% Profyle 95% Tramalin Bloodmine 67% Spinalin Neckpain 38% 19% Inflameless Fungalin Value Split Products 14 to 26 61 130
40
Value Split Stomax Bloodpump Ferexis 19% 1% 10% 57% 38% 29% GPs
Retail Pharmacies Pediatrician Gynecologist - Obstetri.. Internal Medicine Surgery Orthopedics Psychiatry Otolaryngology Cardiologists Dermatology Urology Neurologists Pulmonologist Oncology Nurse Oncologist Endocrinologist Nefrologist Rheumatologist Mastologists Stomax 19% 1% 10% 57% Bloodpump 38% Ferexis 29% Value Split Products 27 to 29 62 130
41
Value Split Stomax Bloodpump Ferexis 38% 10% 19% Neurosurgery
Trauma Specialist Hematologist Anesthesiologists Infect. Spec. Allergist Emergency Spec. Geriatrician Patients Institutions (Promotion.. Patient Advocacy Groups Nurses Stomax Bloodpump 38% 10% Ferexis 19% Value Split Products 27 to 29 63 130
42
2018 Long Term Business impact by customer type
This chart shows where the impactable business* will be coming from over the next 5 years. It is often very interesting to see how this compares with your promotional investment. * Impactable business is defined as the Net Long term Incremental Sales as determined by the PromoPlanner Sales Response analysis. 14% GP 84% Specialist 2% Retail 0% Patient 0% Institution 64 130
43
Description S Painex Antifectum Boforce Cardio Plus Amelin Luistene
29 % 17 % 10 % 0 % 4 % 1 % 2 % 7 % 3 % 19 % 16 % 6 % Products 1 to 20 Base Plan Optimized Alert Level GPs Retail Pharmacies Pediatrician Gynecologist - Obstetrician Internal Medicine Surgery Orthopedics Psychiatry Otolaryngology Cardiologists Dermatology Urology Neurologists Pulmonologist Oncology Nurse Oncologist Endocrinologist Nefrologist Rheumatologist Mastologists S 234 145 Under Over 28 1.07 3.8 23 4.5 5.5 4.1 5.3 10.8 5.0 9.9 8.1 1.99 Painex 1.30 1.54 0.53 0.26 0.29 Antifectum Boforce 1.60 3.7 0.34 2.8 0.60 Cardio Plus 4.9 1.08 Amelin 17.2 2.6 Luistene 1.90 0.10 0.12 Levigra 2.1 1.09 0.73 0.25 Motox 4.4 0.58 0.50 Urofax 4.0 12.3 2.2 5.6 Lempra 9.4 18.2 6.1 6.7 Sertrum 12.1 1.66 Etanos 10.4 3.6 Ingenuine 5.7 Quaxter 32 11.3 6.8 0.45 Kerzan 0.48 Taxis 7.1 Lysine 10.1 1.53 0.67 0.86 Cartox 11.9 Medecks 11.5 2.7 5.1 Profyle 4.8 Description This report extends the information on the previous FTE allocation report to the customer dimension. To achieve this result the PromoPlanner has used the information you supplied during the Customer Landscape exercise. This may result in a slightly different total brand FTE recommendation than on the earlier report, usually a little smaller. This result is more accurate. 65 130
44
Description S Painex Antifectum Boforce Cardio Plus Amelin Luistene
1 % 2 % 0 % 5 % 11 % Products 1 to 20 Base Plan Optimized Alert Level Neurosurgery Trauma Specialist Hematologist Anesthesiologists Infect. Spec. Allergist Emergency Spec. Geriatrician Patients Institutions (Promotion Not Required) Patient Advocacy Groups Nurses S 234 145 Under Over 7.8 6.6 15.3 Painex 1.30 1.54 0.46 Antifectum Boforce 1.60 3.7 Cardio Plus 4.9 Amelin 17.2 Luistene 1.90 0.34 Levigra 2.1 1.09 Motox 4.4 1.08 Urofax 4.0 12.3 Lempra 9.4 18.2 Sertrum 12.1 1.66 Etanos 6.7 10.4 1.88 Ingenuine 5.7 Quaxter 32 11.3 Kerzan 0.48 Taxis 7.1 Lysine 10.1 1.53 Cartox 28 11.9 Medecks 11.5 4.1 Profyle 4.8 5.6 Description This report extends the information on the previous FTE allocation report to the customer dimension. To achieve this result the PromoPlanner has used the information you supplied during the Customer Landscape exercise. This may result in a slightly different total brand FTE recommendation than on the earlier report, usually a little smaller. This result is more accurate. 66 130
45
Description S Tramalin Bloodmine Spinalin Neckpain Inflameless
29 % 17 % 10 % 0 % 4 % 1 % 2 % 7 % 3 % 19 % 16 % 6 % Products 21 to 29 Base Plan Optimized Alert Level GPs Retail Pharmacies Pediatrician Gynecologist - Obstetrician Internal Medicine Surgery Orthopedics Psychiatry Otolaryngology Cardiologists Dermatology Urology Neurologists Pulmonologist Oncology Nurse Oncologist Endocrinologist Nefrologist Rheumatologist Mastologists S 234 145 Under Over 28 1.07 3.8 23 4.5 5.5 4.1 5.3 10.8 5.0 9.9 8.1 1.99 Tramalin Bloodmine 17.4 10.1 2.1 Spinalin 7.5 Neckpain 2.7 2.5 Inflameless 3.1 0.38 Fungalin Stomax Bloodpump 9.5 2.4 0.18 1.34 Ferexis 29 1.94 Description This report extends the information on the previous FTE allocation report to the customer dimension. To achieve this result the PromoPlanner has used the information you supplied during the Customer Landscape exercise. This may result in a slightly different total brand FTE recommendation than on the earlier report, usually a little smaller. This result is more accurate. 67 130
46
Description S Tramalin Bloodmine Spinalin Neckpain Inflameless
1 % 2 % 0 % 5 % 11 % Products 21 to 29 Base Plan Optimized Alert Level Neurosurgery Trauma Specialist Hematologist Anesthesiologists Infect. Spec. Allergist Emergency Spec. Geriatrician Patients Institutions (Promotion Not Required) Patient Advocacy Groups Nurses S 234 145 Under Over 7.8 6.6 15.3 Tramalin Bloodmine 17.4 10.1 6.0 1.96 Spinalin 7.5 5.0 Neckpain 2.7 3.8 1.28 Inflameless 3.1 0.38 Fungalin 4.1 Stomax Bloodpump 9.5 2.4 0.58 0.33 Ferexis 29 1.94 Description This report extends the information on the previous FTE allocation report to the customer dimension. To achieve this result the PromoPlanner has used the information you supplied during the Customer Landscape exercise. This may result in a slightly different total brand FTE recommendation than on the earlier report, usually a little smaller. This result is more accurate. 68 130
47
Plan of Action Short Description Comment
Internal Medicine / Team Trauma Team Short Description This chart shows the promotional investment curve that you are able to deploy profitably on the named Customer Specialty taking into account the products being carried by the selected Sales Force team. It also shows the sales force investment annual calls you have decided to deploy(Reach & Frequency), together with any non sales force driven promotional channel investments you have chosen to deploy. Comment Enter Comment here. 72 130
48
Plan of Action Short Description Comment
Cardiologists / Team CardioVascular Team Short Description This chart shows the promotional investment curve that you are able to deploy profitably on the named Customer Specialty taking into account the products being carried by the selected Sales Force team. It also shows the sales force investment annual calls you have decided to deploy(Reach & Frequency), together with any non sales force driven promotional channel investments you have chosen to deploy. Comment Enter Comment here. 76 130
49
Plan of Action Short Description Comment Dermatology / Team GP Team
This chart shows the promotional investment curve that you are able to deploy profitably on the named Customer Specialty taking into account the products being carried by the selected Sales Force team. It also shows the sales force investment annual calls you have decided to deploy(Reach & Frequency), together with any non sales force driven promotional channel investments you have chosen to deploy. Comment Enter Comment here. 77 130
50
Promo Plan by Customer Short Description Comment Cardiologists
This is your optimized Promotional Plan for the Customer Specialty. Comment Enter Comment here. 95 130
51
Promo Plan by Customer Short Description Comment Neurologists
This is your optimized Promotional Plan for the Customer Specialty. Comment Enter Comment here. 98 130
52
Plan of Action Short Description Comment
Retail Pharmacies / Team Retail Pharmacy Team Short Description This chart shows the promotional investment curve that you are able to deploy profitably on the named Customer Specialty taking into account the products being carried by the selected Sales Force team. It also shows the sales force investment annual calls you have decided to deploy(Reach & Frequency), together with any non sales force driven promotional channel investments you have chosen to deploy. Comment Enter Comment here. 70 130
53
Plan Summary – By Product
2019 Current State of Plan from the Specialty Summary screen output Page 1/3 Products FTEs Promo Investment Non FTEs Total Sales Incremental Sales (Sales Response Short Term Gross) Long Term Gross) Profit Response Long Term Promo. ROI Totals 142 16,882,786 11,065,109 27,947,895 159,715,779 54,333,921 324,729,186 63,109,026 326% Painex 1.54 183,308 57,707 241,015 1,000,925 432,684 1,880,722 588,623 344% Antifectum 0% Boforce 3.0 360,832 126,810 487,642 4,805,290 822,553 3,347,554 1,229,091 352% Cardio Plus 5.5 652,091 848,435 30,906,486 1,280,117 296% Amelin 17.2 2,038,716 2,680,086 88,953,567 4,386,249 315% Luistene 0.34 40,352 50,072 90,423 610,276 173,243 534,040 223,259 347% Levigra 1.11 131,693 119,275 250,968 2,756,968 447,751 1,673,079 601,457 340% Motox 1.08 128,264 283,391 411,655 2,597,526 780,369 2,734,258 991,133 341% Urofax 11.4 1,351,140 526,795 1,877,935 9,919,849 3,263,811 15,315,656 3,899,655 308% Lempra 16.7 1,985,519 739,181 2,724,700 14,837,362 4,564,576 19,932,911 7,237,184 366% 112 130
54
Plan Summary – By Product
2019 Current State of Plan from the Specialty Summary screen output Page 2/3 Products FTEs Promo Investment Non FTEs Total Sales Incremental Sales (Sales Response Short Term Gross) Long Term Gross) Profit Response Long Term Promo. ROI Totals 142 16,882,786 11,065,109 27,947,895 159,715,779 54,333,921 324,729,186 63,109,026 326% Sertrum 1.66 196,994 258,148 455,142 5,145,007 1,734,978 3,072,680 1,191,177 362% Etanos 10.4 1,240,323 430,156 1,670,478 12,568,180 3,000,561 11,699,166 3,782,084 Ingenuine 5.7 681,697 739,665 1,421,362 6,693,440 2,637,419 8,666,083 3,475,781 345% Quaxter 11.3 1,342,296 533,167 1,875,464 8,198,461 3,344,776 12,372,321 4,197,752 324% Kerzan 0.48 56,626 374,288 430,914 3,380,943 827,104 2,769,431 1,160,416 369% Taxis 278,927 1,891,768 639,905 859,801 442,033 258% Lysine 1.36 161,563 387,151 548,714 2,326,205 1,043,452 3,463,451 1,191,897 317% Cartox 11.9 1,414,897 301,322 1,716,219 30,618,399 3,701,517 13,508,617 6,299,706 467% Medecks 1,418,172 513,278 1,931,450 11,727,004 3,626,509 15,002,107 4,761,786 347% Profyle 5.6 663,661 144,478 808,139 4,498,969 1,729,555 8,551,081 2,759,838 442% 113 130
55
Plan Summary – By Product
2019 Current State of Plan from the Specialty Summary screen output Page 3/3 Products FTEs Promo Investment Non FTEs Total Sales Incremental Sales (Sales Response Short Term Gross) Long Term Gross) Profit Response Long Term Promo. ROI Totals 142 16,882,786 11,065,109 27,947,895 159,715,779 54,333,921 324,729,186 63,109,026 326% Tramalin 286,831 354,113 11,890,093 -215,119 25% Bloodmine 10.1 1,202,397 739,526 1,941,923 10,752,891 4,365,911 19,292,527 5,695,305 393% Spinalin 5.0 591,317 458,931 1,050,248 1,089,345 1,633,132 10,769,201 2,335,970 322% Neckpain 3.8 451,858 523,006 974,865 6,140,476 1,883,939 8,801,132 2,134,618 319% Inflameless 0.38 45,527 504,457 544,539 832,826 3,398,751 592,342 217% Fungalin 5,756,481 0% Stomax 577,125 1,311,648 -432,838 Bloodpump 2.6 313,149 246,675 559,824 2,491,610 1,387,231 4,294,878 1,359,092 343% Ferexis 1.94 230,393 1,910,274 2,140,667 9,363,865 6,265,835 19,727,945 1,940,417 191% 114 130
56
Above/Below Recommended
Plan Summary – By Specialty 2019 Current State of Plan from the Specialty Summary screen output Page 1/4 Products FTEs Promo Investment Non FTEs Total Above/Below Recommended Incremental Sales (Sales Response Short Term Gross) Long Term Gross) Profit Response Long Term Promo. ROI Totals 142 16,882,786 11,065,109 27,947,895 -8,621,124 54,333,921 324,729,186 63,109,026 326% GPs 28 3,308,473 1,728,200 5,036,673 -176,985 9,389,563 54,458,428 9,022,453 179% Retail Pharmacies 1.07 127,105 221,140 348,245 -265,793 696,931 2,734,769 831,354 239% Pediatrician 3.8 450,647 393,202 843,849 -97,291 1,773,982 23,115,858 1,677,202 199% Gynecologist - Obstetrician 918,741 -158,200 2,410,217 7,427,477 1,378,277 150% Internal Medicine 19.3 2,292,307 1,352,801 3,645,107 -253,190 6,721,186 26,129,182 7,480,567 205% Surgery 4.5 531,264 169,839 701,103 40,274 1,215,875 4,683,389 1,422,821 203% Orthopedics 5.5 649,527 225,917 875,444 -46,068 1,547,602 5,949,469 1,875,288 214% Psychiatry 354,113 14,894 815,491 10,343,374 220,933 62% Otolaryngology 4.1 486,518 344,212 830,730 -54,675 1,478,215 5,467,914 1,848,255 222% Cardiologists 6.1 721,987 104,895 826,882 49,153 1,390,686 27,021,861 1,704,782 206% 115 130
57
Above/Below Recommended
Plan Summary – By Specialty 2019 Current State of Plan from the Specialty Summary screen output Page 2/4 Products FTEs Promo Investment Non FTEs Total Above/Below Recommended Incremental Sales (Sales Response Short Term Gross) Long Term Gross) Profit Response Long Term Promo. ROI Totals 142 16,882,786 11,065,109 27,947,895 -8,621,124 54,333,921 324,729,186 63,109,026 326% Dermatology 10.8 1,287,979 -34,306 1,685,041 55,927,479 2,552,492 198% Urology 4.5 535,551 245,332 780,883 -137,476 1,425,864 6,618,069 1,889,870 242% Neurologists 5.0 591,317 599,372 1,190,688 -133,643 1,910,668 11,650,299 2,726,400 229% Pulmonologist 41,323 -995 94,801 127,378 65,486 158% Oncology Nurse 85,863 -202,661 194,046 562,436 274,931 320% Oncologist 9.9 1,178,907 395,130 1,574,037 -2,822,565 3,566,178 11,927,747 5,832,621 371% Endocrinologist 8.1 964,541 472,970 1,437,511 -1,217,466 2,663,018 10,414,917 4,013,949 279% Nefrologist 1.99 235,990 110,344 346,334 -115,265 599,697 2,305,986 773,541 223% Rheumatologist 527,706 -282,695 963,393 3,721,203 1,020,548 193% Mastologists 0% 116 130
58
Above/Below Recommended
Plan Summary – By Specialty 2019 Current State of Plan from the Specialty Summary screen output Page 3/4 Products FTEs Promo Investment Non FTEs Total Above/Below Recommended Incremental Sales (Sales Response Short Term Gross) Long Term Gross) Profit Response Long Term Promo. ROI Totals 142 16,882,786 11,065,109 27,947,895 -8,621,124 54,333,921 324,729,186 63,109,026 326% Neurosurgery 0% Trauma Specialist 7.8 921,290 607,301 1,528,591 -702,275 2,975,706 12,560,693 3,997,423 262% Hematologist 6.6 784,738 602,170 1,386,908 -1,136,405 3,180,101 13,489,123 4,047,790 292% Anesthesiologists 3,824 -16,191 8,646 37,581 16,072 420% Infect. Spec. 36,967 -52,268 73,337 245,556 107,045 290% Allergist Emergency Spec. 101,985 -175,114 215,381 1,006,187 288,264 283% Geriatrician 15.3 1,814,644 1,350,019 3,164,663 -516,109 7,191,437 26,269,869 7,818,926 247% Patients 22,574 -50,495 47,815 166,568 73,892 327% Institutions (Promotion Not Required) 49,173 -77,313 99,046 366,371 147,843 301% 117 130
59
Above/Below Recommended
Plan Summary – By Specialty 2019 Current State of Plan from the Specialty Summary screen output Page 4/4 Products FTEs Promo Investment Non FTEs Total Above/Below Recommended Incremental Sales (Sales Response Short Term Gross) Long Term Gross) Profit Response Long Term Promo. ROI Totals 142 16,882,786 11,065,109 27,947,895 -8,621,124 54,333,921 324,729,186 63,109,026 326% Patient Advocacy Groups 0% Nurses 118 130
60
Team Structure (Summary)
Comparison of Base Case Team Structure vs Planned Team Structure Page 1/1 Base Case Plan Team FTEs Calls Made Calls Planned Totals 234 142 GP Team 72 39 Geriatrican Team 20.0 24 Endocrine Team 8.1 18.1 CardioVascular Team 17.6 12.7 Trauma Team 37 12.8 Pain Team 17.7 9.9 7692 Oncology Team 5.9 11.9 7168.8 Paediatrican Team 12.3 7.9 Psychiatry/Neurology Team 11.7 5.0 3252.8 Retail Pharmacy Team 31 1.07 883.2 119 130
61
Customers Speciality Visited
Team Structure (Detail) Comparison of Base Case Team Structure vs Planned Team Structure GP Team Page 1/2 Customers Speciality Visited Base Case Plan Planned Team Bag FTEs Calls Made Customer Weighting Calls Planned Products Carried Product Weighting Team Totals 72 100% 39 GPs 42 59% 28 72% Amelin 35% Dermatology 2.4 3% 10.8 8949.6 28% Quaxter 17% Pediatrician 15.4 21% Lempra 14% Urology 9.7 13% Medecks 7% Allergist 1.29 1062.2 2% Neckpain Gynecologist - Obstetrician 1.05 868.56 1% Urofax 6% Rheumatologist 0.08 62.04 0% Ferexis 5% Nefrologist 0.05 41.36 Cardio Plus Levigra Painex Kerzan Inflameless 120 130
62
Customers Speciality Visited
Team Structure (Detail) Comparison of Base Case Team Structure vs Planned Team Structure CardioVascular Team Page 1/1 Customers Speciality Visited Base Case Plan Planned Team Bag FTEs Calls Made Customer Weighting Calls Planned Products Carried Product Weighting Team Totals 17.6 100% 12.7 Hematologist 1.85 11% 6.6 5112 52% Bloodmine 47% Cardiologists 11.9 68% 6.1 48% Cardio Plus 35% GPs 1.38 8% Bloodpump 17% Internal Medicine 0.97 748.24 6% Levigra 1% Neurologists 0.51 398.56 3% Geriatrician 392.92 Endocrinologist 0.21 165.44 Rheumatologist 0.11 82.72 Surgery 0.05 41.36 0% Psychiatry 39.48 Orthopedics 0.03 20.68 124 130
63
Customers Speciality Visited
Team Structure (Detail) Comparison of Base Case Team Structure vs Planned Team Structure Oncology Team Page 1/1 Customers Speciality Visited Base Case Plan Planned Team Bag FTEs Calls Made Customer Weighting Calls Planned Products Carried Product Weighting Team Totals 5.9 100% 11.9 7168.8 Oncologist 1.89 32% 9.9 83% Cartox Nefrologist 1.99 17% Pulmonologist 1.73 1043.4 29% Oncology Nurse 1.00 603.48 GPs 0.63 377.88 11% Internal Medicine 0.38 227.48 6% Hematologist 0.27 165.44 5% 127 130
64
Customers Speciality Visited
Team Structure (Detail) Comparison of Base Case Team Structure vs Planned Team Structure Retail Pharmacy Team Page 1/1 Customers Speciality Visited Base Case Plan Planned Team Bag FTEs Calls Made Customer Weighting Calls Planned Products Carried Product Weighting Team Totals 31 100% 1.07 883.2 Retail Pharmacies 30 97% Quaxter 42% Rheumatologist 0.36 293.28 1% Painex 24% Surgery 0.23 186.12 Levigra 23% Pulmonologist 0.20 165.44 Luistene 11% Gynecologist - Obstetrician 0.13 103.4 0% Otolaryngology 0.05 41.36 Neurologists Pediatrician 0.03 20.68 130
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.